KOBE March 16, 2020 - Carna Biosciences Inc. (JASDAQ: 4572) today announced that it has entered into a license agreement with BioNova Pharmaceuticals Limited (BioNova) to develop and commercialize AS-1763, a novel next-generation non-covalent Bruton's tyrosine kinase (BTK) inhibitor for the Greater China territory.
NEW YORK November 7, 2019 – Kadmon Holdings, Inc. (NYSE: KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in the People’s Republic of China.